Recent developments in SARS‐CoV‐2 vaccines: A systematic review of the current studies

SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron

(2022) Alison Tarke et al.   CELL

Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance

(2022) Jiahui Chen et al.   Journal of Chemical Information and Modeling

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

(2021) Raches Ella et al.   LANCET INFECTIOUS DISEASES

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

(2021) Jerald Sadoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

(2021) Kathryn E. Stephenson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

(2021) Denis Y Logunov et al.   LANCET

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

(2021) Peter Richmond et al.   LANCET

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

(2021) Zhiwei Wu et al.   LANCET INFECTIOUS DISEASES

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

(2021) Raches Ella et al.   LANCET INFECTIOUS DISEASES

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine

(2021) Laurence Chu et al.   VACCINE

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

(2021) Ulf M Geisen et al.   ANNALS OF THE RHEUMATIC DISEASES

Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis

(2021) Ayelet Grupper et al.   Clinical Journal of the American Society of Nephrology

Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients – a prospective cohort study

(2021) Osnat Itzhaki Ben Zadok et al.   EUROPEAN JOURNAL OF HEART FAILURE

Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women

(2021) Ai-ris Y. Collier et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

(2021) Liane Rabinowich et al.   JOURNAL OF HEPATOLOGY

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

(2021) Katherine R W Emary et al.   LANCET

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

(2021) Shilong Yang et al.   LANCET INFECTIOUS DISEASES

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study

(2021) Paul A Goepfert et al.   LANCET INFECTIOUS DISEASES

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

(2021) Keith J Chappell et al.   LANCET INFECTIOUS DISEASES

Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors

(2021) Barliz Waissengrin et al.   LANCET ONCOLOGY

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

(2021) Leticia Monin et al.   LANCET ONCOLOGY

Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19

(2021) Brian J. Ward et al.   NATURE MEDICINE

Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study

(2021) Jingxin Li et al.   NATURE MEDICINE

Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared to healthy controls

(2021) Benedikt Simon et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

(2021) Shabir A. Madhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

(2021) Jerald Sadoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

(2021) Vivek Shinde et al.   NEW ENGLAND JOURNAL OF MEDICINE

The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18–59 years: A phase I randomized, double-blinded, controlled trial

(2021) Jing Pu et al.   VACCINE

Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)

(2021) Johannes Korth et al.   Viruses-Basel

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis

(2021) Michael Jahn et al.   Vaccines

Impaired anti‐SARS‐CoV‐2 humoral and cellular immune response induced by Pfizer‐BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients

(2021) Monica Miele et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Effectiveness of SARS‐CoV‐2 vaccination in fully vaccinated solid organ transplant recipients

(2021) Maricar Malinis et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2

(2021) Yolanda Braun-Moscovici et al.   ANNALS OF THE RHEUMATIC DISEASES

Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease

(2021) Rebecca H Haberman et al.   ANNALS OF THE RHEUMATIC DISEASES

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia

(2021) Patrick Harrington et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer

(2021) Alfredo Addeo et al.   CANCER CELL

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

(2021) Oliver Van Oekelen et al.   CANCER CELL

Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial

(2021) Ya-Jun Shu et al.   CHINESE MEDICAL JOURNAL

Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients

(2021) René Schramm et al.   Clinical Research in Cardiology

The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience

(2021) Gabriel Revon-Riviere et al.   EUROPEAN JOURNAL OF CANCER

High levels of anti–SARS-CoV-2 IgG antibodies in previously infected patients with cancer after a single dose of BNT 162b2 vaccine

(2021) Dominic Fong et al.   EUROPEAN JOURNAL OF CANCER

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults

(2021) Nawal Al Kaabi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity

(2021) David Hagin et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients

(2021) Jan Havlin et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients: a multicenter prospective observational pilot study

(2021) Paul Lesny et al.   JOURNAL OF NEPHROLOGY

Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients

(2021) Clément Danthu et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

(2021) Mine Durusu Tanriover et al.   LANCET

Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms

(2021) Patrick Harrington et al.   LEUKEMIA

High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients

(2021) Nathalie Longlune et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

(2021) Alejandro Jara et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

(2021) Robert W. Frenck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

(2021) Paul T. Heath et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

(2021) Hana M. El Sahly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

(2021) Stephen J. Thomas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early experience with SARs‐CoV‐2 mRNA vaccine breakthrough among kidney transplant recipients

(2021) Chelsey Chenxi Song et al.   Transplant Infectious Disease

A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18–59 Years: An Interim Analysis in Indonesia

(2021) Eddy Fadlyana et al.   VACCINE

Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2

(2021) Peter G. Kremsner et al.   WIENER KLINISCHE WOCHENSCHRIFT

Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study

(2021) Kazimieras Maneikis et al.   Lancet Haematology

Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines

(2021) Madhusudhanan Narasimhan et al.   Vaccines

Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis

(2021) Andrea Rubbert-Roth et al.   Lancet Rheumatology

Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients

(2021) José Jesús Broseta et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

(2021) Raches Ella et al.   LANCET

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa

(2021) Shirley Collie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

(2021) Sue Ann Costa Clemens et al.   Nature Communications

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial

(2021) Neil Formica et al.   PLOS MEDICINE

Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

(2020) Aiping Wu et al.   Cell Host & Microbe

Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2

(2020) Zhixin Liu et al.   JOURNAL OF MEDICAL VIROLOGY

China’s response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak response

(2020) John Nkengasong   NATURE MEDICINE

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

(2020)   Nature Microbiology

Epidemiology of and Risk Factors for Coronavirus Infection in Health Care Workers

(2020) Roger Chou et al.   ANNALS OF INTERNAL MEDICINE

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

(2020) Ling Ni et al.   IMMUNITY

SARS-CoV-2 Vaccines: Status Report

(2020) Fatima Amanat et al.   IMMUNITY

Comparison of SARS-CoV-2 spike protein binding to ACE2 receptors from human, pets, farm animals, and putative intermediate hosts

(2020) Xiaofeng Zhai et al.   JOURNAL OF VIROLOGY

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

(2020) Feng-Cai Zhu et al.   LANCET

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

(2020) Hui Wang et al.   CELL

A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice

(2020) Dorottya Laczkó et al.   IMMUNITY

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes

(2020) Shengli Xia et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

(2020) Feng-Cai Zhu et al.   LANCET

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

(2020) Pedro M Folegatti et al.   LANCET

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults

(2020) Mark J. Mulligan et al.   NATURE

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

(2020) Kizzmekia S. Corbett et al.   NEW ENGLAND JOURNAL OF MEDICINE

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development

(2020) Atin Khalaj-Hedayati   Journal of Immunology Research

Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System

(2020) Ruodan Xu et al.   Frontiers in Bioengineering and Biotechnology

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

(2020) Denis Y Logunov et al.   LANCET

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

(2020) Shengli Xia et al.   LANCET INFECTIOUS DISEASES

The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19

(2020) Amir Hossein Mansourabadi et al.   LIFE SCIENCES

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

(2020) Ugur Sahin et al.   NATURE

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

(2020) Edward E. Walsh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

(2020) Evan J. Anderson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

(2020) Cheryl Keech et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cold-Adapted Live Attenuated SARS-Cov-2 Vaccine Completely Protects Human ACE2 Transgenic Mice from SARS-Cov-2 Infection

(2020) Sang Heui Seo et al.   Vaccines

Dysregulation of the immune response in coronavirus disease 2019

(2020) Leila Mohamed Khosroshahi et al.   CELL BIOLOGY INTERNATIONAL

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

(2020) Maheshi N Ramasamy et al.   LANCET

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

(2020) Jordan R. Barrett et al.   NATURE MEDICINE

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

(2020) Yanjun Zhang et al.   LANCET INFECTIOUS DISEASES

mRNA vaccines — a new era in vaccinology

(2018) Norbert Pardi et al.   NATURE REVIEWS DRUG DISCOVERY

Virus-like particle vaccines: immunology and formulation for clinical translation

(2018) Braeden Donaldson et al.   Expert Review of Vaccines

Influenza vaccine: Where are we and where do we go?

(2018) Mohsen Keshavarz et al.   REVIEWS IN MEDICAL VIROLOGY

Major findings and recent advances in virus–like particle (VLP)-based vaccines

(2017) Mona O. Mohsen et al.   SEMINARS IN IMMUNOLOGY

Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)

(2015) Tom T. Shimabukuro et al.   VACCINE